Comparative Pharmacology
Head-to-head clinical analysis: LOCORTEN versus TOPICORT LP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOCORTEN versus TOPICORT LP.
LOCORTEN vs TOPICORT LP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit prostaglandin and leukotriene synthesis, reduce cytokine release, and suppress immune cell activation.
Topicort LP (desoximetasone) is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to intracellular glucocorticoid receptors, leading to modulation of gene expression that suppresses inflammatory mediators such as prostaglandins, leukotrienes, and cytokines.
For mild to moderate dermatoses: Apply a thin film to affected area twice daily. For severe dermatoses: Apply a thin film to affected area three to four times daily. Topical use only. Not for ophthalmic use.
Apply a thin film to the affected skin areas twice daily. Route: topical. Frequency: twice daily.
None Documented
None Documented
100 hours (terminal). Clinical context: prolonged in hepatic impairment; single daily dosing sufficient for psoriasis.
Terminal elimination half-life is approximately 2-4 hours after topical application. This short half-life reflects rapid systemic clearance and minimal accumulation with once-daily dosing.
Renal: ~75% (inactive metabolites); biliary/fecal: ~25%. <1% unchanged.
Primarily renal (urinary excretion of metabolites and unchanged drug). Biliary/fecal elimination is minimal, accounting for <5% of the dose.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid